Figure S8 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR⁺/HER2⁻ Breast Cancer

Xiu-Zhi Zhu; Hu-Yun-Long Zhang; Yi-Fan Zhou; Yi-Yu Chen; Tong Fu; Ming-Liang Jin; Ya-Xin Zhao; Yi-Fan Xie; Xiaohua Zeng; Xi Jin; Yi‐Zhou Jiang; Zhi‐Ming Shao

doi:10.1158/0008-5472.30363466

October 15, 2025

Figure S8 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR⁺/HER2⁻ Breast Cancer

View at Publisher

Ask AI

Bookmark

Share

Key Points

Precision treatment improves outcomes in HR+/HER2− breast cancer subtypes by tailoring therapy based on characteristics.
Distinct SNF subtypes of HR+/HER2− breast cancer show varying clinicopathologic profiles, supporting personalized treatment strategies.
The analysis of early-stage, real-world cohorts highlights the potential of subtyping in enhancing therapeutic efficacy.
This research underscores the need for targeted treatment approaches rather than traditional one-size-fits-all therapy.

Implication

Observational analysis reveals distinct clinicopathologic characteristics in HR+/HER2− breast cancer subtypes, highlighting implications for treatment.

Abstract

Fig. S8 Clinicopathologic characteristics of HR+/HER2- breast cancer grouped by SNF subtype in early-stage real-world cohorts.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Zhu et al. (2025) studied this question.

synapsesocial.com/papers/68f199bfde32064e504dcade https://doi.org/10.1158/0008-5472.30363466

View at Publisher

Ask AI

Bookmark

Share

Figure S8 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR⁺/HER2⁻ Breast Cancer

Key Points

Implication

Abstract

Discussion

Cite This Study

Figure S8 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR⁺/HER2⁻ Breast Cancer

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading